Search

Search Constraints

You searched for: Author/Creator Grange, Florent

Search Results

2. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021)

3. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021)

4. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. (November 2022)

5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Issue 13 (October 2015)

6. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Issue 6 (December 2017)

7. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib. (September 2021)

8. French real-life retrospective study in patients with mycosis fungoides and Sezary syndrome treated by mogamulizumab. (October 2021)

9. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. (14th December 2015)

10. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. (14th December 2015)